Financial Data and Key Metrics Changes - The company achieved a record adjusted EBITDA of $35.9 million for Q2 2025, with adjusted EBITDA margins of 20.6% and base business free cash flow of $37.4 million, all exceeding expectations [4][5] - Year-over-year, total revenue increased by 1%, while adjusted EBITDA rose by $5.2 million or 17% [5][6] - The adjusted EBITDA for 2025 is projected to be $68.1 million, which is $3.1 million above the upper range of guidance provided in Q1 2025 [5] Business Line Data and Key Metrics Changes - Completion Fluids and Products adjusted EBITDA margins increased by 100 basis points to 36.7% from 35.7%, supported by the CS Neptune jobs [6] - Industrial chemicals grew by 5.5% year-over-year, continuing to outpace both U.S. and global GDP growth [6][7] - Water and Flowback services revenue remained flat compared to Q1 but decreased by 10% year-over-year, outperforming U.S. frac activity which declined by 14% quarter-over-quarter and 26% year-over-year [7][8] Market Data and Key Metrics Changes - The U.S. rig count has been in decline for sixteen months, contributing to overall market uncertainty [5][6] - Despite declining U.S. land activity, produced water volumes are expected to increase, with TETRA recording its first revenue from Permian Basin produced water desalination [10][12] - The company is seeing strong forecast projections for energy storage electrolyte needs, with expected growth in utility-scale energy storage capacity [13][15] Company Strategy and Development Direction - TETRA is focused on strategic growth initiatives, including the Arkansas bromine processing facility, which is expected to produce significant incremental revenues and adjusted EBITDA at full capacity [16] - The company is pursuing a license model for desalination projects to minimize capital expenditures and avoid diluting shareholder value [25][26] - TETRA aims to maintain a leverage ratio below two times EBITDA while investing in growth opportunities [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term outlook for completion fluids and products, driven by strong market positions in key areas [7][21] - The company anticipates a healthy pipeline of Neptune projects and expects a record year for deepwater activity in 2025, despite a projected decline in second-half activity compared to the first half [21][22] - Management highlighted the importance of automation technology and produced water treatment in offsetting declines in U.S. land completions [20][82] Other Important Information - TETRA's Investor Day is scheduled for September 25, 2025, where the company will provide insights into operational performance and financial prospects [3][28] - The company has increased its cash balance by $32 million, improving its net leverage ratio to 1.2 times trailing twelve months EBITDA [25][26] Q&A Session Summary Question: Inquiry about desalination project economics and legislative initiatives - Management discussed the increasing costs of disposal well operations and the decreasing costs of desalination solutions, highlighting supportive regulatory changes such as Texas House Bill 49 [34][35][36] Question: Offshore completion market and customer conversations - Management noted strong trends in deepwater activity and higher pressure wells, which align with TETRA's strengths in completion fluids [40] Question: Guidance for the second half of the year - Management expects activity levels to be consistent between Q3 and Q4, with a record year overall despite a decline in deepwater activity [43] Question: Factors driving revenue guidance - Management emphasized the strong overall deepwater activity and the importance of upcoming projects in 2026, while EOS volumes are expected to ramp up significantly [51][52] Question: Securing bromine supply for Arkansas project - Management confirmed ongoing discussions with multiple bromine suppliers to ensure supply meets demand for the Arkansas facility [65][66] Question: Progress on desalination and commercial plants - Management indicated a shift towards small commercial plants rather than additional pilot operations, reflecting growing confidence from customers [67][68]

Tetra Technologies (TTI) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this oil and gas services company would post earnings of $0.08 per share when it actually produced earnings of $0.11, delivering a surprise of +37.5%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Tetra ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) Commission File Number 1-13455 TETRA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 74-2148293 (State or Other Jurisdic ...

TETRA TECHNOLOGIES, INC. ANNOUNCES STRONG SECOND QUARTER 2025 RESULTS AND PROVIDES FULL YEAR GUIDANCE Second Quarter 2025 Financial Highlights Exhibit 99.1 THE WOODLANDS, TEXAS, July 29, 2025 / PR Newswire / - TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced second quarter 2025 financial results. Brady Murphy, TETRA President and Chief Executive Officer, stated, "Our employees delivered an exceptional second quarter with Adjusted EBITDA of $35.9 million, adjusted EBITDA margins of 20 ...

Financial Performance - TETRA Technologies reported a second quarter 2025 revenue of $173.9 million, an 11% sequential increase from $157.1 million in the first quarter of 2025 [4][5] - Adjusted EBITDA for the second quarter was $35.9 million, up from $32.3 million in the previous quarter, reflecting a margin of 20.6% [2][5] - Net income before taxes for the second quarter was $19.4 million, a significant increase of $14.4 million sequentially [5][4] Segment Performance - Completion Fluids & Products segment revenue increased by 18% sequentially and 9% year-over-year, with adjusted EBITDA margins rising to 36.7% [6][7] - Water & Flowback Services revenue remained flat despite a 14% decline in U.S. frac activity, with adjusted EBITDA margins decreasing to 10% [8][9] Cash Flow and Balance Sheet - The company generated $48.3 million in net cash from operating activities during the second quarter, with total adjusted free cash flow of $26.5 million [20][5] - As of June 30, 2025, TETRA had cash and cash equivalents of $69 million and a net leverage ratio of 1.2 times adjusted EBITDA [22][21] Growth Initiatives - TETRA is advancing its Arkansas bromine processing facility project, having invested $44 million since 2024, with expectations to generate incremental revenue of $200 million to $250 million at full production [11][10] - The company is also focusing on emerging growth markets, including energy storage and produced water recycling, with significant potential for reshaping its business profile [13][19] Full Year Guidance - For the full year 2025, TETRA expects GAAP net income before taxes to be between $21 million and $34 million, with adjusted EBITDA projected between $100 million and $110 million [3]

Core Viewpoint - TETRA Technologies, Inc. is set to release its second quarter 2025 results on July 29, 2025, followed by a conference call to discuss the results on July 30, 2025 [1] Group 1: Upcoming Events - The second quarter 2025 results will be announced after market close on July 29, 2025, with a conference call scheduled for July 30, 2025, at 10:30 a.m. Eastern Time [1] - TETRA will host an Investor Day on September 25, 2025, at the New York Stock Exchange, where the executive team will outline strategic objectives and growth initiatives for the next five years [3] Group 2: Communication and Accessibility - Investors can listen to the conference call by calling a toll-free number or via live audio webcast, with a replay available for one week after the call [2] - Presentation materials for the Investor Day will be available on TETRA's Investor Relations website, and advance registration is required for attendance [3] Group 3: Company Overview - TETRA Technologies, Inc. operates globally across six continents, focusing on energy services, industrial chemicals, and critical minerals [4] - The company is expanding into the low-carbon energy market, leveraging its chemistry expertise and global infrastructure to meet sustainable energy demands [4]

Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EUJune 25, 2025 9:00 AM EDT | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic conditions, today announced that the Co ...

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders [2][10] - The company is publicly traded on the TSX Venture Exchange and OTCQX [10] Clinical Programs - The company is advancing two lead Phase 2 clinical programs for its novel thiol drug, TTI-0102 [3] - A European multicenter trial for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS), initiated on May 14, 2025 [3] - A U.S.-based trial for the Leigh Syndrome Spectrum (LSS), following FDA clearance of the Investigational New Drug (IND) application on June 11, 2025 [3] Drug Candidate - TTI-0102 is a next-generation thiol-based prodrug designed to enhance intracellular levels of glutathione and taurine, which are critical for mitigating oxidative stress in mitochondrial disorders [3][8] - The drug is engineered to address challenges faced by first-generation thiol-based drugs, including short half-life and adverse side effects [8] Mitochondrial Disorders - MELAS is characterized by symptoms such as seizures, muscle weakness, and can lead to loss of motor skills and intellectual disability, affecting approximately 4.1 in 100,000 of the population [7] - LSS is diagnosed in about 1 in 40,000 births and presents symptoms like impaired feeding, loss of motor skills, and seizures, with no current cure available [6] Conference Participation - The company’s CEO, Dr. Patrice Rioux, will participate in a clinical panel discussion at the United Mitochondrial Disease Foundation's 2025 Mitochondrial Medicine Conference, which gathers over 700 scientists and industry stakeholders [2][3]

Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides UpdateJune 17, 2025 9:00 AM EDT | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation o ...

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, California, publicly traded on the TSX Venture Exchange and OTCQX [2] - The company is focused on developing sulfur-containing prodrugs aimed at treating serious pediatric diseases with unmet medical needs [2] Product Development - Thiogenesis' lead product candidate, TTI-0102, is currently in an active Phase 2 clinical trial for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) [2] - The company is planning to initiate clinical trials for additional conditions including Leigh syndrome, Rett syndrome, and pediatric MASH [2] Recent Corporate Actions - On June 11, 2025, the company's board of directors approved a grant of 400,000 common share purchase options at an exercise price of $0.77 to two directors [1] - The options will vest at a rate of 25% every six months and will expire on June 11, 2030 [1]